JP6122418B2 - アンチトロンビンｉｉｉ結合部位を２個含む多糖、これの調製および抗血栓薬剤としてのこれの使用 - Google Patents

アンチトロンビンｉｉｉ結合部位を２個含む多糖、これの調製および抗血栓薬剤としてのこれの使用 Download PDF

Info

Publication number
JP6122418B2
JP6122418B2 JP2014504429A JP2014504429A JP6122418B2 JP 6122418 B2 JP6122418 B2 JP 6122418B2 JP 2014504429 A JP2014504429 A JP 2014504429A JP 2014504429 A JP2014504429 A JP 2014504429A JP 6122418 B2 JP6122418 B2 JP 6122418B2
Authority
JP
Japan
Prior art keywords
polysaccharide
formula
iii
fraction
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014504429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511929A5 (https=
JP2014511929A (ja
Inventor
ムリエ，ピエール
ビスコブ，クリスチヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2014511929A publication Critical patent/JP2014511929A/ja
Publication of JP2014511929A5 publication Critical patent/JP2014511929A5/ja
Application granted granted Critical
Publication of JP6122418B2 publication Critical patent/JP6122418B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B01D15/1878—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series for multi-dimensional chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014504429A 2011-04-11 2012-04-11 アンチトロンビンｉｉｉ結合部位を２個含む多糖、これの調製および抗血栓薬剤としてのこれの使用 Active JP6122418B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1153116 2011-04-11
FR1153116 2011-04-11
PCT/IB2012/051768 WO2012140580A1 (en) 2011-04-11 2012-04-11 Polysaccharides comprising two antithrombin iii-binding sites, preparation thereof and use thereof as antithrombotic medicaments

Publications (3)

Publication Number Publication Date
JP2014511929A JP2014511929A (ja) 2014-05-19
JP2014511929A5 JP2014511929A5 (https=) 2015-04-02
JP6122418B2 true JP6122418B2 (ja) 2017-04-26

Family

ID=46025830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504429A Active JP6122418B2 (ja) 2011-04-11 2012-04-11 アンチトロンビンｉｉｉ結合部位を２個含む多糖、これの調製および抗血栓薬剤としてのこれの使用

Country Status (7)

Country Link
US (2) US9346894B2 (https=)
EP (1) EP2697265B1 (https=)
JP (1) JP6122418B2 (https=)
AR (1) AR085961A1 (https=)
TW (1) TW201247209A (https=)
UY (1) UY34012A (https=)
WO (1) WO2012140580A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2818871A1 (en) 2013-06-28 2014-12-31 Roche Diagniostics GmbH Means and methods for universal calibration of anti-Factor Xa tests
CN103743837B (zh) * 2013-12-24 2015-01-21 山东泰邦生物制品有限公司 人抗凝血酶ⅲ肝素结合比例检测方法
KR102240937B1 (ko) * 2014-10-10 2021-04-15 삼성디스플레이 주식회사 표시 장치
CN107431362A (zh) * 2014-11-06 2017-12-01 曼蒂斯影像有限公司 提供能量脉冲的电路
JP6741277B2 (ja) * 2015-12-30 2020-08-19 シェンツェン ヘパリンク ファーマスーティカル グループ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｈｅｐａｌｉｎｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用
CN111175415A (zh) * 2019-12-24 2020-05-19 湖北亿诺瑞生物制药有限公司 一种依诺肝素钠中苄索氯铵残留的测定方法
EP4384819A1 (en) 2021-08-08 2024-06-19 University of Rochester Nanomembrane device and method for biomarker sampling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663639B1 (fr) 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
FR2845686B1 (fr) * 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FR2889078B1 (fr) 2005-07-27 2007-11-02 Aventis Pharma Sa Nouvelle methode de chromatographie d'affinite d'antithrombine iii

Also Published As

Publication number Publication date
WO2012140580A1 (en) 2012-10-18
EP2697265A1 (en) 2014-02-19
AR085961A1 (es) 2013-11-06
TW201247209A (en) 2012-12-01
US9346894B2 (en) 2016-05-24
US20140031316A1 (en) 2014-01-30
JP2014511929A (ja) 2014-05-19
UY34012A (es) 2012-11-30
US20160310521A1 (en) 2016-10-27
EP2697265B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
JP6122418B2 (ja) アンチトロンビンｉｉｉ結合部位を２個含む多糖、これの調製および抗血栓薬剤としてのこれの使用
Bisio et al. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin
Pervin et al. Preparation and structural characterization of large heparin-derived oligosaccharides
Linhardt et al. Structure and activity of a unique heparin-derived hexasaccharide.
Alekseeva et al. Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments
Razi et al. Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide
WO2013139478A1 (en) Profiling oligosaccharides associated with biological activities of heparin or heparin derivatives
EP2427503B1 (en) Novel acylated decasaccharides and their use as antithrombotic agents
Mourier et al. Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin
Alban et al. Gas-liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfates
Yu et al. Filter-entrapment enrichment pull-down assay for glycosaminoglycan structural characterization and protein interaction
Zhang et al. Structure and pharmacokinetics/pharmacodynamics of the anticoagulant tetradecasaccharide oHG-14 as an intrinsic tenase inhibitor
EP2427502B1 (en) Novel sulfated octasaccharide and its use as antithrombotic
EP2427198A1 (en) Use of an acylated octasaccharide as antithrombotic agent
EP2427500B1 (en) Novel acylated 1,6-anhydro decasaccharide and its use as antithrombotic agent
Zhu et al. Comprehensive chromatographic profiling and structural analysis of key anticoagulant components in enoxaparin
Li et al. Bottom-up LMWH analysis using LC-FTMS for extensive characterization
Urso et al. Structural variation in the linkage region of pharmaceutical heparin arising from oxidative treatments during manufacture
Risi PHYSICAL-CHEMICAL CHARACTERIZATION OF POLYSACCHARIDES AND THEIR INTERACTION WITH PROTEINS
Wang Preparation and characterization of heparin-derived oligosaccharides and their applications
MXPA06009628A (en) Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
HK1140220A (en) Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150210

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170321

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170331

R150 Certificate of patent or registration of utility model

Ref document number: 6122418

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250